Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.79
Bid: 93.35
Ask: 93.36
Change: -0.20 (-0.22%)
Spread: 0.01 (0.011%)
Open: 92.56
High: 92.71
Low: 90.28
Prev. Close: 90.87
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares slip overall but German blue-chips hit record high

Fri, 28th Jul 2023 17:31

STOXX 600 dips 0.2% but posts weekly gains

*

Germany's DAX hits record high

*

BOJ policy tweak lifts European yields

*

Capgemini slides as Q2 growth slows

July 28 (Reuters) - European shares retreated from multi-month highs on Friday after a mixed bag of earnings and a surprise Bank of Japan policy tweak, but German blue-chips bucked the trend to close at a record high on signs of cooling inflation.

The pan-European STOXX 600 index ended 0.2% lower after closing at its highest level in nearly 1-1/2 years on Thursday when the European Central Bank hiked interest rates as expected but raised the possibility of a pause in September.

Rattling investor nerves, the BoJ made its yield curve control policy more flexible and loosened its defence of a long-term interest rate cap, in moves seen as a prelude to an eventual shift away from the massive monetary stimulus.

"We have the last of the accommodative central banks moving away from accommodative policies," said Steve Sosnick, chief strategist at Interactive Brokers.

"The fear of this BOJ move was because it can really affect hedge funds' carry trade...there was a fear that this could really spiral out from Japan yields (but) it hasn't happened."

Germany's DAX index hit an intraday record and held on to most of the gains to close 0.39% higher after data showed inflation resumed a downward trend in Europe's largest economy.

However, separate data showed the economy stagnated in the second quarter of 2023, missing forecasts for modest growth

Elsewhere, Spanish consumer prices rose by a more than anticipated 2.3% in the 12 months through July.

Despite Friday's weakness, the benchmark STOXX 600 notched up a third straight week of gains, on hopes that the Federal Reserve and the ECB are nearly done hiking interest rates.

Tech stocks and miners were among the week's top gainers, adding 3.6% and 3.4% respectively.

Hermes rose 3.9% as sales at the Birkin bag maker accelerated in the second quarter, while AstraZeneca advanced 3.3% after reporting forecast-beating profit and sales.

French drugmaker Sanofi slipped 2.9% as quarterly sales fell short of estimates, and French IT consulting group Capgemini tumbled 7.0% on a bigger-than-expected slowdown in second-quarter growth.

Austrian sensor maker AMS Osram jumped 18.5% after the company presented a strategic re-alignment of the group and reported second-quarter results in line with its expectations.

Pan-European stock and derivatives exchange Euronext climbed 7.4%, boosted by the launch of a 200-million-euro ($219.88 million) share buyback programme. (Reporting by Sruthi Shankar, Amruta Khadekar and Shristi Achar A in Bengaluru; Editing by Kirsten Donovan)

More News
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
10 May 2024 17:21

STOXX 600 closes at record high on earnings, rate cut optimism

Rio Tinto considered bid for BHP-target Anglo American -report

*

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.